Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (Diluted Average) (2019 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Outstanding (Diluted Average) for 7 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 128.96% to $61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.9 million through Dec 2025, up 128.96% year-over-year, with the annual reading at $61.9 million for FY2025, 128.96% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $61.9 million at Whitehawk Therapeutics, up from $39.9 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $61.9 million in Q4 2025, with the low at $2.5 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $24.9 million, with a median of $26.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) plummeted 93.78% in 2021, then surged 724.84% in 2022.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $8.9 million in 2021, then surged by 152.27% to $22.5 million in 2022, then increased by 19.58% to $26.9 million in 2023, then grew by 0.42% to $27.0 million in 2024, then skyrocketed by 128.96% to $61.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $61.9 million, $39.9 million, and $27.0 million for Q4 2025, Q1 2025, and Q4 2024 respectively.